Navigation Links
Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Date:8/23/2007

SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will present updated results from its Phase 2 trial of picoplatin, including one-year survival data, during a poster discussion session at the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer in Seoul, Korea. Details follow:

Poster number: PD6-1-1

Title: A phase 2 study of picoplatin monotherapy for patients with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy

Presenter: David A. Karlin, M.D., senior vice president, clinical development and regulatory affairs, at Poniard

Date: Monday, September 3, at 4:00 p.m. local time

Location: Room 310 of the Coex Convention Center

About Picoplatin

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the U.S. Food and Drug Administration (FDA) in November 2005 for picoplatin for the treatment of SCLC.

Poniard is currently evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Poniard is also evaluating intravenous pi
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
(Date:5/23/2013)... Calif. , May 23, 2013 Amgen (NASDAQ: ... 38 th Annual  Healthcare Conference on Thursday, May 30, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... at Amgen, will present at the conference. Live audio of ... Amgen,s website, www.amgen.com , under Investors. A replay of ...
(Date:5/23/2013)... 2013  MGC Diagnostics Corporation (NASDAQ: MGCD ... today scheduled a conference call to discuss its financial ... ended April 30, 2013. The call will be at ... Company will report financial results for the second quarter ... Thursday, May 30, 2013. (Logo: ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... Cardica, Inc. (Nasdaq: CRDC ) today ... marketing. In this role, Mr. Littel will be responsible ... Cardica,s existing cardiac surgery devices and its planned MicroCutter™ ... surgery. "Chris brings experience as a successful ...
... -- ShangPharma Corporation (NYSE: SHP ) ... and biotechnology research and development outsourcing company, today ... subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner"), acquired the ... River") Shanghai research facility. As ...
Cached Medicine Technology:Cardica Appoints Christopher Littel VP, Sales and Marketing 2Cardica Appoints Christopher Littel VP, Sales and Marketing 3ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Let’s face it: ... is not uncommon for the majority of people to be ... is due to a coffee addiction or simply genetics, yellowish ... procedures are so popular. , Herald Square Dental ... very effective whitening system: Venus White Max. , Teeth ...
(Date:5/24/2013)... 24, 2013 Area homeowners dreaming about owning ... hot tubs to choose from at factory-direct pricing during the ... sales event takes place at Emerald Pool and Patio ... , Jacuzzi, the industry's leading hot tub brand, scheduled the ... country. The event will feature popular hot tub models at ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... 2013 BestSatelliteProviders.com the online satellite ... of consumers compare the features and services offered ... recently released the rankings of the best ... for viewing on their website. , ... to Adam Matthews, the spokesperson for BestSatelliteProviders.com, “When ...
Breaking Medicine News(10 mins):Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2
... therapy may encourage prostate cancer cells to produce a ... the body, a new study by Johns Hopkins researchers ... to changes in this standard treatment for a sometimes ... discovery is far too preliminary for prostate cancer patients ...
... well as slight changes in eating behavior, could explain ... narcolepsy, according to a study published in the October ... authored by Dorothe Chabas, MD, PhD, of the Fdration ... on 13 patients with narcolepsy and nine healthy controls ...
... studies that have indicated the speed with which adolescents can ... Medical School have conducted the first study to determine why ... not. , We know that nicotine can have an ... that not every adolescent who tries a cigarette gets hooked, ...
... in mice that surgeons and cardiologists may be able ... , The research, published in the October issue of ... the British Heart Foundation and conducted by Saadeh Suleiman, ... and his colleagues at the Bristol Heart Institute. It ...
... suggestion questioned by experts , , SUNDAY, Sept. 30 (HealthDay ... more likely to visit emergency rooms or be hospitalized ... the finding of a new study that reaches the ... may underlie these racial disparities." , However, that genetics ...
... to not stop statin drug use , , ... disease should not stop taking cholesterol-lowering drugs before any ... this week by the American Heart Association and the ... update those published in 2002, provide a framework for ...
Cached Medicine News:Health News:Standard treatment for prostate cancer may encourage spread of disease 2Health News:Lower metabolism, eating behavior possibly explain the cause of overweight in narcolepsy 2Health News:Initial reaction to nicotine can dictate addiction 2Health News:New research suggests hearts are experts at self-preservation 2Health News:Do Blacks Have Genetic Weakness to Asthma? 2Health News:Take Care of Heart Before Any Surgery: Experts 2
Compact tray features all components for urethral catheterization....
Inquire...
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... immunoassay for the quantification of NT-proBNP in ... Elecsys proBNP assay helps to rule-out efficiently ... also indicate the severity of the disease ... addition, NT-proBNP facilitates monitoring, allowing for the ...
Medicine Products: